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Abstract 
Mares in estrus can exhibit erratic and fractious behavior that may adversely 
affect their ease of handling. Current treatments for suppression of estrus in the mare 
include an oral progestin, Regu-mate® (Hodgson et al., 2005),  uterine insertion of a glass 
ball (Nie et al., 2003), fetal crushing through rectal palpation (Lefranc, 2004) and surgical 
sterilization (McCue, 2003).  Although effective, all of these procedures are problematic 
for different reasons.  Immunization against an endogenous hormone critical to fertility is 
an attractive alternative in suppressing estrus; especially if it is less intrusive and 
reversible.  This strategy has been demonstrated by targeting gonadotropin-releasing 
hormone (GnRH) in gilts (Esbenshade and Britt, 1985), ewes (Clarke et al., 1978), mares 
(Garza et al., 1986), and heifers (Johnson et al., 1988).   
The antigen developed for this study was produced using the sequence of the 
bacterial protein, glutathione-S-transferase (GST) linked to three in-tandem repeats of the 
mammalian GnRH gene coding sequence (GST-GnRH3).  Six reproductively sound 
mares, between the ages of 3 and 8 years, were used in this study. The anti-GnRH group 
(n=4) received 1 mg of GST-GnRH3 in 2ml of incomplete Freund’s adjuvant (IFA) as 
the primary injection.  Four weeks later, mares received a single booster injection of 
0.5mg of GST-GnRH3 in 1ml of IFA. The control mares (n=2) received similar doses of 
GST protein only, in identical injection volumes of IFA as the anti-GnRH group.  The 
entire duration of the study ran for 22 weeks from early May through September.  
 
 Ovaries were monitored three times weekly to track follicular growth and 
ovulation via transrectal ultrasonography. In addition, all mares were exposed to a 
stallion twice weekly and observed for estrous behavior. Weekly blood samples were 
collected to evaluate progesterone levels and serum binding of GnRH.   
The GST-GnRH3 antigen suppressed follicular activity in all treatment mares 
within 45 days following the second injection. Estrous behavior was suppressed in all but 
one mare in the anti-GnRH group. When exposed to the stallion, this mare displayed 
strong estrous behavior for seven weeks despite her lack of ovarian cyclicity. Follicular 
activity and estrous behavior remained normal in one of the control mares (avg. cycle 
length = 20 days). For the final 10 weeks of the study, however, the other control mare 
developed large follicles but failed to ovulate according to the ultrasound data. This mare 
did not display estrous behavior during this period, and her progesterone levels remained 
greater than 2 ng/ml for most of the final 10 weeks of the study.  Approximately 2 weeks 
after the booster injection all anti-GnRH mares had progesterone levels of <1ng/ml. 
GnRH antibody binding peaked two weeks following booster immunization in all treated 
mares and remained undetectable in control mares throughout the study.  
The GST-GnRH3 treatment induced GnRH binding, suppressed follicular activity 
and reduced progesterone concentrations in all four mares.   Although estrous behavior 
was abolished in 3 of the 4 treated mares, one did continue to demonstrate estrous 
behavior in the presence of a stallion.  This dissociation of ovarian activity and estrous 
behavior was evident in our study with a limited number of animals, but the vaccine does 
show promise in reducing unwanted estrous behavior.   
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CHAPTER 1 - Review of Literature 
Estrous Cycle of the Mare 
Horses are seasonal polyestrous breeders and mares in the Northern Hemisphere, 
in general, have estrous cycles beginning early spring and continuing through mid-fall.  
However, the reproductive cycle of the mare is more variable than any other domestic 
species and anestrous is not necessarily consistent throughout the winter months (Ginther, 
1992).  One of the most important environmental signals for controlling estrus and 
anestrous is photoperiod.  During short day months the pineal gland secretes melatonin 
suppressing estrus in the mare, in contrast to long day months when melatonin secretion 
is low and allowing for persistent waves of follicular development.       
The mare’s estrous cycle is approximately 21 days long beginning with 5-7 
consecutive days of sexual receptivity (standing estrus).  Ovulation usually occurs on 
days 3, 4, or 5 of the estrous cycle with behavioral estrus subsiding 24 to 48 hours after 
ovulation.  A follicle stimulating hormone (FSH) surge at 1-2 weeks prior to ovulation 
initiates the growth and selection of the dominant follicle.  Luteinizing hormone (LH) 
secretion in the mare is unique to other domestic species.  In contrast to a quick burst, LH 
concentrations gradually increase during the follicular phase reaching maximum 
concentrations 1-2 days after ovulation and then slowly decline over the next 4-6 days 
(Ginther, 1992).    
Gonadotropin-Releasing Hormone (GnRH) is composed of a highly conserved 10 
amino acid sequence (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) and is a 
fundamental regulator of reproductive function through initiation of the hypothalamic-
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pituitary-gonadal axis (Schally, 1975).  Neurosecretory cells located in the medial basal 
hypothalamus synthesize and release GnRH into the hypothalamo-hypophyseal portal 
circulation enabling small quantities of hormone to be deposited in the primary portal 
plexus of the pituitary stalk (Senger, 2004).  GnRH is rapidly transferred to a second 
capillary bed within the anterior pituitary and binds to GnRH-receptors expressed by the 
pituitary gonadotropes.   
GnRH hormone-receptor binding initiates synthesis and release of gonadotropin 
hormones through signal transduction.  Phosphorylation of guanosine diphosphate (GDP) 
on the intracellular G protein-coupled receptor alpha subunit (Gα) initiates activation of 
the phospholipase C (PLC) signaling pathway.  PLC hydrolyses the phosphodiester link 
in phosphotidylinostitol 4,5 bisphosphate (PIP2), cleaving it into second messengers 
inositol triphosphate (IP3) and transmembrane diacylglycerol (DAG).  IP3 quickly 
diffuses through the cytosol to the endoplasmic reticulum (ER) where it binds to a ligand 
gated calcium (Ca2+) channel allowing release of Ca2+ into the cytosol.  DAG activates  
protein kinase C (PKC) stimulating synthesis of the gonadotropins, luteinizing hormone 
(LH) and follicle stimulating hormone (FSH).  Release of LH and FSH into the 
circulation results from the   influx and accumulation of calcium as well as PKC (Hirota 
et al., 1985).  
Gonadotropins bind to receptors expressed on cells of developing follicles to 
stimulate follicular growth and ovulation.  Granulosa cells in developing follicles 
synthesize and secrete the steroid hormone estrogen, which in turn acts on the 
hypothalamus to increase synthesis and secretion of GnRH, causing the LH surge 
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required for ovulation.  After ovulation the corpus luteum develops and will secrete 
progesterone which inhibits GnRH concentrations.        
Estrus Prevention 
Typically it is a producer’s goal to enhance the fertility in livestock species.  This 
is obviously important for breeding stock, but in other production situations suppression 
or abolition of estrus and its associated behavior is advantageous.  For example, there are 
several negative economic factors associated with heifers entering the feedlot pregnant 
including reduced average daily gain, decreased dressing percentage and the risk of 
calving in the feedlot (Sewell, 1993).  Owners of performance, ranch, show or racing 
horses tend to devalue mares due to aggression and inattentive behavior exhibited during 
the 5-7 days of estrus (N. Edward Robinson, 2008).  Handling of some mares in estrus 
can be difficult and dangerous due to their aggressive and obstinate demeanor.  While 
estrous behavior is most apparent when the mare is in close proximity to a stallion, 
aggression and decreased response to commands can be demonstrated under any 
circumstance during estrus.  The peak of sexual receptivity is characterized by lowering 
of the pelvis and spreading hind limbs, lifting of the tail, exposing the perineal region by 
rhythmic eversions of the clitoris, and frequent urination (Crowell-Davis, 2007).  At these 
times it is impractical and potentially dangerous to use these animals, as they often 
attempt to bite or kick other horses.  In an effort to eliminate these problems several 
methods of suppressing estrus and estrous behavior in mares have been explored.  
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Progesterone Treatments 
The most common method of suppressing estrus in mares is by the use of 
progesterone and synthetic progestins.  High levels of progesterone suppress the release 
of hypothalamic GnRH which reduces pituitary output of LH and FSH thereby 
suppressing follicular growth and estrogen concentrations known to induce estrous 
behavior.  Progesterone, in an oil base, was shown to effectively suppress cyclicity and 
estrous behavior in mares when injected intramuscularly at a dose of 100 mg daily or 400 
mg every other day (Loy and Swan, 1966).  However, weekly administration can cause 
moderate to severe site reactions and muscle soreness.  Medroxyprogesterone acetate 
(MPA) was investigated as another off-label use of progesterone for suppressing estrus in 
mares (Gee et al., 2008).  In this study, an initial dose (1.6 g) of compounded MPA with 
subsequent weekly doses of 400 mg did not suppress estrous behavior or follicular 
development in any of the treated mares.  Progesterone-estradiol benzoate (Synovex-S® 
implants; Syntex Animal Health, Des Moines, Iowa), labeled for use in cattle to promote 
feed efficiency and weight gain, were investigated as a method of suppressing estrus in 
mares (McCue, 1997).  A normal dose of Synovex-S® consists of 8 implants equivalent 
to 200 mg of progesterone and 20 mg of estradiol benzoate.  In this study estrous activity 
was not suppressed in mares receiving 0, 8, 32 or 80 implants 5 days post-ovulation.  
Alternatively, oral administration of the synthetic progesterone Regu-mate® 
(Altrenogest, Intervet Inc, Millsboro, DE) is labeled for use to help maintain pregnancy 
and delay estrus in cycling mares, and is widely used for performance and show horses.  
Altrenogest has shown to be 94% effective at suppressing estrous behavior and follicular 
development when administered daily for 15 days (Webel and Squires, 1982).  Of the 
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mares that displayed estrus during the treatment period, some displayed estrus for the first 
5-8 days while others displayed sporadic estrous behavior or remained in estrus the entire 
duration of the treatment.  Daily doses of Regu-mate® (0.44 mg/kg) placed on the back 
of mare’s tongue can be difficult to administer, expensive (approximately $2.50 - $4.00 a 
day) and must be handled with care as it is readily absorbed through skin which could 
cause a disruption of menstrual cycles of women. 
Oxytocin Treatments 
Oxytocin during the equine luteal phase is not thought to be secreted by the CL to 
the same degree as other domestic species (Stevenson et al., 1991).  However, it was 
reported that repeated injections of oxytocin during the midluteal phase was effective at 
prolonging the luteal phase in the mare (Stout et al., 1999; Vanderwall, 2007).  A recent 
study demonstrated that injections of oxytocin every 12 hours from days 7-14 post-
ovulation prolonged the CL and held progesterone levels above 1ng/ml for approximately 
60 days (Vanderwall, 2007).  More research is needed to improve our understanding of 
the impact that oxytocin has on estrus suppression and associated behavior in mares.    
Uterine Glass Ball 
Uterine insertion of a glass ball (UGB) has been a technique used to suppress 
behavioral estrus in the mare by prolonging the luteal phase and sustaining high 
progesterone levels.  While the method of action by which the luteal phase is prolonged is 
unclear, the UGB may mimic a conceptus and movement around the uterus inhibits 
endometrial release of prostaglandin preventing luteolysis (Nie et al., 2003).  A study of 
the efficacy of UGB treatment found that insertion of a ball approximately 35 mm in 
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diameter 24 hours post ovulation prolonged luteal function for up to 87 days post-
ovulation in 39% of mares.  A smaller 25 mm UGB was less effective as it was expelled 
in 50% of the mares tested, while no expulsion occurred in mares receiving a 35 mm 
UGB (Nie et al., 2003).  Insertions of UGBs are effective at maintaining progesterone 
levels above 1ng/ml, and may serve as an alternative to daily administration of 
progesterone.  This method is an easy, inexpensive and reversible method of suppressing 
estrus in the mare.  However, the low efficacy rate, the possibility of microbial 
contamination and the need for monitoring cyclic activity to determine the time of 
insertion followed by removal of the ball makes it an unattractive method for many horse 
owners. 
Surgical Sterilization 
A more common procedure used to suppress estrous behavior and prevent 
pregnancy, compared to use of a UGB or manually reducing pregnancy, is surgical 
sterilization or ovariectomy.  It is speculated that in most domestic species initiation of 
estrous behavior is due to ovarian steroid hormones, and by removing the ovaries such 
behavior would be eliminated.  However, studies have shown that this is not always true 
and that continuous estrous behavior in the absence of ovarian activity has been observed 
in some ovariectomized, anovulatory, or mares with small inactive ovaries (Asa et al., 
1980; Dalin et al., 2002; Hooper, 1993; Kamm and Hendrickson, 2007).  It was also 
reported that the probability of an ovariectomized or anovulatory mare showing estrus 
behavior is higher on any given day than it is for an intact mare during the ovulatory 
season (Asa et al., 1979).  This frequent behavior qualifies these females as good 
candidates for use as jump mares on breeding farms but can be problematic for a 
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performance horse owner.  Irregular estrous patterns observed in anovulatory and 
ovariectomized mares could be the result of specific social compositions of mares teased 
in groups or due to individual mare preference for certain stallions  (Asa et al., 1980).  
Moreover, estrous behavior in mares with inactive ovaries may be initiated by the release 
of estrogenic steroids from the adrenals (Asa et al., 1980; Crowell-Davis, 2007), 
suggesting estrous behavior displayed by ovariectomized or anovulatory mares may be 
due to low progesterone levels and circulating adrenal estrogens.  Due to the 
unpredictable behavior after surgery and irreversibility of this method, it is not an ideal 
procedure for owners of mares that would like to reduce or eliminate typical behaviors 
associated with mares in estrus. 
Immunocontraception 
Immunization against an endogenous hormone critical to fertility is referred to as 
immunocontraception.  The method by which immunocontraception initiates an immune 
response and suppresses estrus is through initiation of humoral immunity involving the 
proliferation of B immune cells and their production of antibody proteins.  Upon primary 
immunization, a short burst of the immunoglobulin IgM is secreted by B cells as the 
initial response to neutralize the newly recognized antigen.  The IgM response is 
associated with the action of innate immune cells which process and clear the antigen 
before presenting antigen to B cells to stimulate production of specific immunoglobulins.  
Subsequent exposure to the same antigen results in a secondary immune response 
involving the secretion of the memory immunoglobulin IgG.  This secondary immune 
response is slightly delayed and IgG is secreted at a much higher concentration and for 
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longer periods of time than IgM secretion to ensure the binding, destruction and clearance 
of antigen.  
    In order to elicit an immune response to an endogenous reproductive hormone, 
a mimicking antigen must be linked to a foreign carrier protein.  Antibodies will be 
produced against the foreign protein-hormone complex.  These hormone-specific 
antibodies generated will cross react with the endogenous hormone and prevent it from 
reaching its target tissue. This methodology is an attractive alternative to other methods 
of reducing fertility and has been demonstrated to suppress estrus in horses by targeting 
the reproductive hormone gonadotropin-releasing hormone (Dalin et al., 2002; Elhay et 
al., 2007; Garza et al., 1986; Imboden et al., 2006; Tshewang et al., 1997).   
Typically, the source of protein hormone used as antigens are chemically 
synthesized or purified from tissues and then chemically conjugated to a foreign carrier 
molecule.  One disadvantage of this procedure is the variation of immunogenicity in 
antigen preparations as a result of the purification and conjugation procedures (Grieger 
and Reeves, 1990).  As an alternative, the DNA coding sequence for a specific peptide 
can be linked to a bacterial carrier molecule DNA sequence through recombinant DNA 
engineering.   
Anti-GnRH Vaccine in the Mare 
An early study investigated the effects of a GnRH conjugated to bovine serum 
albumin vaccine on the secretion of LH and FSH (Garza et al., 1986).  Mares received an 
immunization of 4.0 mg of the GnRH conjugate in Freund’s complete adjuvant, followed 
4 weeks later by a 2.0 mg dose of antigen in Freund’s incomplete, which was then 
administered every 6 weeks until ovariectomy at week 30.  Findings from this study 
 8
concluded that this anti-GnRH vaccine successfully suppressed plasma concentrations of 
progesterone, LH and to a lesser extent FSH while increasing tritiated GnRH binding 
after the third immunization.  
  Recently, commercial conjugate anti-GnRH vaccines such as Improvac® (Pfizer 
Animal Health P/L, West Ryde, NSW, Australia)  and Equity™ (Pfizer Animal Health 
P/L, West Ryde, NSW, Australia) have been evaluated as effective methods of 
suppressing estrus in the mare (Elhay et al., 2007; Imboden et al., 2006).  Improvac®, 
commonly used in Australia to treat against boar taint, was administered to 9 mares on 
weeks 0 and 4 (Imboden et al., 2006).  Follicular development and progesterone 
concentrations were suppressed following the second injection, however sporadic estrous 
behavior of the Improvac® treated mares was observed throughout the duration of the 
study.  Similarly, two injections of Equity™ administered 4 weeks apart successfully 
suppressed follicular development and progesterone levels, but was not capable of 
suppressing estrous behavior in all mares (Elhay et al., 2007).  Equity™ is currently 
approved for use in fillies and mares to suppress estrous behavior and activity in 
Australia.     
Recombinant DNA Technology 
The use of recombinant DNA technology eliminates the need for tissue 
purification of protein and conjugation steps (Johnson et al., 1988).  Recombinant DNA 
is the incorporation of two or more sources of DNA to construct a new recombinant 
molecule.  This technology is an attractive alternative to conjugation of tissue-purified 
protein due to the similarity and repeatability between batches of recombinant antigen.  A 
recombinant glutathione S- transferase-GnRH vaccine (Koster and Grieger, 1995) was 
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effective in abolishing estrous cycles in yearling beef heifers (Holladay et al., 2003).  Use 
of recombinant DNA technology in a vaccine against GnRH was described by Zhang et 
al. (1999) employing ovalbumin as the carrier protein source.  This recombinant GnRH 
vaccine was shown to be effective at suppressing follicular development in mice (Zhang 
et al., 1999), rats (Conforti et al., 2007), rams (Ulker et al., 2005) and cattle (Geary et al., 
2006; Hernandez et al., 2005; Sosa et al., 2000; Stevens et al., 2005).      
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CHAPTER 2 
Suppression of cyclicity and estrous behavior in mares through 
immunization using a recombinant GnRH antigen. 
Introduction 
Typically it is a producer’s goal to enhance the fertility in livestock species.  This 
is obviously important for breeding stock, but in other production situations suppression 
or abolition of estrus and its associated behavior is advantageous.  For many horse 
owners, mares are less valuable than geldings as working or performance horses due to 
gender-related behavior problems such as aggression, focused attention to surroundings, 
and a decreased response to commands.  Ranch or show mares often exhibit behavioral 
problems during estrus that may adversely affect their ease of handling.  At these times it 
is impractical and potentially dangerous to use these animals, as they often attempt to bite 
or kick other horses.  
Current treatments for suppressing estrus in the mare include the oral progestin, 
Regu-mate® (altrenogest, Intervet, Inc. (Hodgson et al., 2005), uterine insertion of a 
glass ball to suppress behavioral estrus (Nie et al., 2003), fetal crushing through rectal 
palpation (Lefranc, 2004), oxytocin treatments (Vanderwall, 2007) and surgical 
sterilization (McCue, 2003).  However, all of these procedures are problematic for 
different reasons.  Regumate must be administered daily, fetal crushing is uncommon and 
often viewed as ethically unaccepted, and surgical sterilization is effective but 
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irreversible.  An effective, non-invasive and reversible method of sterilization would be 
ideal for the horse owner, whether their mares are used for pleasure, show, or ranch and 
feedlot work.  
Immunization against an endogenous hormone critical to fertility is referred to as 
immunocontraception.  This methodology is an attractive alternative to other methods of 
suppressing fertility and has been demonstrated by targeting the reproductive hormone 
gonadotropin-releasing hormone (GnRH) in gilts (Esbenshade and Britt, 1985), ewes 
(Clarke et al., 1978), mares (Garza et al., 1986), and heifers (Johnson et al., 1988). 
Gonadotropin-releasing hormone is a hypothalamic peptide that causes release of 
follicle stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior 
pituitary gland (Hafez and Hafez, 2000). Since the primary roles of FSH and LH are to 
cause follicle growth and ovulation, altering the function of GnRH will disrupt 
reproductive cycles.  However, in order to immunize animals against an endogenous 
“self” protein such as GnRH, the peptide must first be linked to a foreign carrier molecule 
which will induce an immune response.  Typically, the source of protein hormone for use 
as antigens are chemically synthesized or purified from tissues, and then chemically 
conjugated to a carrier molecule.  One disadvantage of this procedure is the variation of 
immunogenicity in antigen preparations as a result of the purification and conjugation 
procedures (Grieger and Reeves, 1990).  As an alternative, the DNA coding sequence for 
GnRH can be linked to a bacterial carrier molecule DNA sequence through use of 
recombinant DNA engineering.  This methodology eliminates the need for tissue 
purification of protein and conjugation steps.  The use of recombinant DNA technology 
to produce fusion proteins can also provide a consistent source of antigen.  Previous 
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studies in our laboratory reported the development of a recombinant GnRH vaccine 
(Koster and Grieger, 1995) that was effective in abolishing estrous cycles in yearling beef 
heifers (Holladay et al., 2003).  In mares it would be ideal to give vaccinations against 
GnRH at selected times of the year to suppress unwanted estrous periods.  Since 
immunocontraception has been shown to be reversible in cattle (Grieger and Reeves, 
1990; Sosa et al., 2000), this may be very beneficial in the equine industry where estrus 
could be suppressed early in a mare’s life, with the option of breeding her when she is 
older.  The objective of this study was to test the use of a recombinant GnRH vaccine as a 
method of inducing temporary sterility in mares.    
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Materials and Methods 
Plasmid Construction 
The construction of the expression plasmid GST-GnRH3 was previously 
described by Holladay and coworkers in 2003 (Figure 1).  The commercial expression 
vector (pGEX-4T-3; GE Healthcare, Piscataway, NJ) was engineered to include three 
tandem copies of the coding sequence for GnRH in-frame and downstream of the 
glutathione-S-transferase coding sequence.  The expression plasmid created was named 
pGEX-GnRH3.  In the current study the plasmid was transformed into E. coli DH5-α 
cells, an attenuated laboratory strain used for plasmid replication and protein expression.  
Transformed cells were streaked onto Luria-Bertani (LB) ampicillin agar plates and 
grown overnight at 37°C.  Resulting colonies were cultured and plasmid DNA was 
isolated using QIAprep® Spin Miniprep Kit (Qiagen, Valencia, CA).  Purified plasmid 
DNA was digested with restriction endonuclease BamH I (New England Biolabs, 
Ipswich, MA) or both BamH I and EcoR V (New England Biolabs).  Digests were 
evaluated on a 2% agarose gel containing ethidium bromide to verify predicted insertion 
size.     
The control vaccine was generated using GST protein from the pGEX-4T-3 
vector.  Vector DNA was digested with BamH I to confirm absence of GnRH3 insert.        
Protein Expression 
 A 25 ml aliquot of an overnight culture of plasmid-transformed DH5-α cells was 
used to inoculate 500 ml of LB ampicillin broth.  The 500 ml flasks remained under 
constant shaking at 37°C until A600 was between 1.0 - 2.0 relative absorptive units.  When 
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the culture reached desired confluence, isopropyl β-D-1-thiogalactopyranoside (IPTG) 
was added to a final concentration of 0.1 mM to induce protein expression. 
A series of four different treatments were investigated to determine which would 
render the greatest yield of soluble fusion protein (GST-GnRH3).  Incubation time and 
solubilizing buffer were the two factors tested.  Time of IPTG incubation was either 
overnight at room temperature or for 3 hours at 37°C.  The solubilizing buffer consisted 
of either lysozyme alone or lysozyme plus sarcosine (Sambrook and Russell, 2001).  
Each treatment culture was replicated twice.  
In treatments using sarcosine buffer, the culture containing IPTG was left to shake 
overnight at room temperature or for 3 hours at 37°C.  After either 3 hours or an 
overnight incubation time, cultures were centrifuged at 3300xg for 20 minutes at 4°C, 
supernatant was discarded and a 1/20 volume of Gibco DPBS was used to resuspend the 
remaining pellet.  Cell walls were disrupted by adding 1 mg/ml lysozyme to the 
resuspended pellet and placed on ice for 30 minutes.  The cell lysate was centrifuged at 
10,000 xg for 10 minutes at 4°C, the supernatant was removed and saved while the pellet 
was solublized in an 8 ml detergent solution containing 1.5% N-lauroylsarcosine, 25 mM 
triethanolamine and 1 mM EDTA (pH 8.0).  The resuspended pellet was mixed on a 
rocker for 10 minutes at 4°C then centrifuged at 10,000 xg for 10 minutes at 4°C.  The 
remaining supernatant was combined with the supernatant from the initial detergent-free 
lysate supernatant and filtered through a 0.45 micron filter.        
In treatments without sarcosine buffer, the culture containing IPTG was left to 
shake overnight at room temperature or for 3 hours at 37°C.  After allowing the correct 
incubation time, cultures were centrifuged at 3300 xg for 20 minutes at 4°C, supernatant 
 15
was discarded and a 1/20 volume of Dulbeco’s Phosphate Buffered Saline (DPBS; 
Invitrogen, Carlsbad, CA) was used to resuspend the remaining pellet.  Cell walls were 
disrupted by adding 1mg/ml lysozyme to the resuspended pellet and placed on ice for 30 
minutes.  Triton X-100 at a 1% concentration was added to the cell lysate and shaken 
vigorously.  DNase (Sigma, St. Louis, MO) and RNase (Sigma) were then added to the 
detergent and lysate at a final concentration of 5µg/ml and mixed on a rocker for 10 
minutes at 4°C.  Centrifugation at 3,000 x g for 30 minutes at 4°C was performed and 
supernatant collected.  Dithiothreitol at a final concentration of 1mM was added to the 
supernatant then filtered through a 0.45 micron filter.   
For production of the control vaccine (GST-only) a 3 hour IPTG incubation 
without sarcosine buffer was used. 
Protein Purification 
Purification of the GST-GnRH3 protein was done with glutathione bound GSTrap 
FF columns (1 ml; GE Healthcare) in conjunction with a peristaltic pump.  Each 
treatment and control vaccine protein was filtered through a 0.45 micron filter and 
assigned to an individual column.  The columns were equilibrated with 5 ml of binding 
buffer (Gibco DPBS) before the sample was applied at a flow rate of approximately 0.7 
ml/min.  The columns were then washed with 10 ml of binding buffer at an increased 
flow rate of approximately 1.3 ml/min and the protein was eluted with a buffer consisting 
of 50 mM Tris-HCl and 10 mM reduced glutathione (pH 8.0; Sigma).  Samples were 
collected in 1ml aliquots and protein concentration quantified using a spectrophotometer 
(Nano Drop ND-1,000).  Total protein isolated from the GSTrapFF columns was 
calculated individually for each treatment type.   
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Approximately 15 mg of GST-GnRH3 protein and 17 mg of GST protein was 
transferred into a dialysis membrane (12,000-14,000 molecular weight cut off) and stirred 
slowly in 4 L of filtered water at 4°C overnight.  The samples were then dried using a 
FTS systems (Stone Ridge, NY) model FD-20-54 lyophilizer and condensed with a TDS-
4A DuraStop tray dryer. 
Western Blots 
Western blot analysis was used to confirm size and specificity of recombinant 
protein.  Bio-Rad precast gels (12% gradient) were loaded with 10 µg of GST-GnRH 
protein, electrophoresed at 200 V for 35 minutes, and stained with Coomassie blue to 
determine size of bands.  An identically loaded gel was electrophoretically transferred to 
a nitrocellulose membrane for western blot analysis.  After a 1 hour 100 V transfer, the 
membrane was cut in half and blocked for 30 minutes with 1X casein.  One half of the 
membrane was probed with goat anti-GST antibody at 1:2000 and the other half was 
probed with rabbit anti-GnRH at 1:100.  Both halves were left to incubate overnight.  
Membranes were washed with 1X casein for 15 minutes prior to a 30 minute incubation 
with either a 1:500 dilution of biotinylated anti-goat antibody or a 1:200 dilution of 
biotinylated anti-rabbit antibody.  The membranes were each washed in 1X casein and 
incubated with prepared Vectastain ABC Reagent (Vector Laboratories, Burlingame, 
CA) for 30 minutes with subsequent washing in 1X casein.  Membranes were placed in a 
TMB substrate solution peroxidase (Vector Laboratories) until desired color development 
occurred; development was stopped with a distilled water rinse and membranes were left 
to air dry.     
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Animals 
All procedures used in the care, handling and sampling of animals in our study 
were approved by the Kansas State University Institutional Animal Care and Use 
Committee.  Six reproductively sound Quarter Horse mares (ages 3 to 8 years) were used.  
Four were assigned to an anti-GnRH treatment (505.91 ± 6.89 kg) and two were assigned 
as controls (515.91 ± 19.55 kg).  Ultrasonography (Sonovet 600; 5mHz linear transducer) 
of ovaries three times per week was used to demonstrate reproductive cyclicity of all 
mares for one month prior to the initial treatment.  Following primary injection and 
throughout the end of the study all mares were continually scanned three times a week 
(Figure 2).  In order to synchronize the estrous cycles for the initiation of treatments, one 
control mare was administered a 10 mg dose of Prostamate (Agrilabs, St. Joseph MO) 8 
days after a recorded ovulation and one anti-GnRH mare received Prostamate (10 mg) 5 
days post-ovulation.  Human chorionic gonadotropin (hCG; 2500 IU; Intervet Inc, 
Millsboro, DE) was administered on day 22 of cycle to induce ovulation in another anti-
GnRH treated mare followed by an injection of Prostamate (10 mg) 5 days post-
ovulation.   
Mares were exposed to a stallion twice weekly to monitor estrous behavior in a 
group setting with the stallion located in a center tease pen.  Each mare was assigned a 
teasing score of 1-5.  A mare received a score of 1 if she showed no interest or exhibited 
aggressive behavior towards the stallion, and received a score of 5 for leaning into the 
stallion, squatting and urinating.  Weekly blood samples were collected via jugular 
venipuncture into 10 ml vacutainers.  Samples were collected for 22 weeks from May 9, 
2008 to October 3, 2008.  Following collection, samples were refrigerated and allowed to 
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clot overnight at 4°C.  Samples were centrifuged and the serum stored at -20°C until 
assayed.          
Immunizations 
Mares in the anti-GnRH treatment group received an intramuscular injection of 
1mg of GST-GnRH3 in 2 ml incomplete Freund’s adjuvant (IFA; Sigma) in the right side 
of the neck.  Four weeks later, mares received a second immunization of 0.5 mg of GST-
GnRH3 in 1ml IFA in the right mid-gluteal region.  The antigen and adjuvant dose was 
reduced in half for the second immunization due to adverse reactions observed following 
the primary injection.  Control mares (n=2) received similar doses of GST protein only in 
identical injection volumes of IFA.  Mares were observed twice daily for the 
development of injection site reactions (heat, pain, swelling)  for 7 days following 
vaccination ; body temperatures of all mares were also recorded twice a day for one week 
following each immunization.  
Hormone Assays 
Serum binding of GnRH was analyzed using an enzyme-linked immunosorbent 
assay (ELISA) as described previously (Holladay et al., 2003).  Nunc brand maxisorp 96-
well microtiter plates (Fisher Scientific, Waltham, MA) were coated with 100 ng/well of 
GnRH peptide (Anaspec, San Jose, CA) in 0.01M carbonate-bicarbonate buffer (Sigma), 
shaken for 1 hour at room temperature and incubated at 4°C overnight.  Plates were 
rinsed with wash buffer (Kirkegaard and Perry Labs, Gaithersburg, MD), blocked for 1 
hour at room temperature with lab buffer (BSA, sodium azide, Tween 40, DTPA) and 
then rinsed with wash buffer.  Serum diluted in lab buffer at 1:100 was added and 
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incubated for 1 hour before being rinsed with wash buffer.  Binding was detected by 
adding 100 µl of a 1:1000 dilution of goat anti-horse IgG horseradish peroxidase (HRP) 
conjugate (Bethyl, Montgomery, TX), incubated for an hour then rinsed with wash 
buffer.  100 µl of the visualizing agent tetramethylbenzidine (TMB; BioFX, Owings 
Mills, MD) was added and left to incubate for 15 minutes before including 100 µl of 450 
stop reagent (BioFX). The plate was read at 450 nm using a Wallac 1430 multilabel 
counter.  Plates were adjusted to eliminate plate variation using a common serum sample.  
Progesterone concentrations were determined by radioimmunoassay as previously 
described (Stevenson, 1981).  For each sample 20 µl of serum was assayed in duplicate.  
The intra-assay CV was 7.6%.  
Statistical Analysis 
Statistical analysis on GnRH binding and progesterone concentration was 
performed with SAS 9.1 (SAS; SAS Institute, Cary NC) using PROC MIXED model.  
GnRH binding and progesterone means before and after second injection were compared 
with treatment as a fixed effect.  Mares were initially included as a random effect but 
were not significant, therefore they were not included in the final model. 
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Results 
Plasmid and Protein Analysis 
BamH I and BamH I/EcoR V digests of the pGEX-GnRH3 plasmid resulted in the 
predicted band sizes of a 90 bp GnRH3 fragment (Figure 3).  A BamH I digest of the 
plasmid produced products of approximately 4970 bp and 90 bp in length, which match 
the predicted size of the vector and GnRH3 insert, respectively (Figure 1).   The BamH 
I/EcoR V digest resulted in products of approximately 3285 bp, 1785bp and 90 bp.  There 
is a unique EcoR V site within the vector sequence which was used to further confirm the 
identity of the plasmid.  A BamH I digest of pGEX-4T-3 vector used to produce control 
protein (GST only) resulted in a single predicted 4968 bp fragment (Figure 4).    
In the two treatments tested to increase fusion protein yield, the amount of total 
protein collected between the two replications was similar.  The 3-hour incubation 
without sarcosine buffer yielded the highest amount of protein (18.9 mg) from the GST 
columns.  Overnight incubation without sarcosine buffer yielded 4.7 mg, overnight 
incubation with sarcosine yielded 1.5 mg, and the 3 hour incubation with sarcosine 
yielded 0.3 mg of protein from the GST columns.        
The GST only vector for control mare immunizations was expressed using the 3-
hour incubation without sarcosine buffer and resulted in 17.0 mg of protein.  
Polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate the GST-
GnRH3 protein by size in order to assess molecular weight (Figure 5).  As a control on 
the gel, 20 ug of bovine serum albumin (BSA) was loaded and displayed a major protein 
at approximately 70 kD.  GST-GnRH3 lanes contained major proteins at approximately 
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25 kD and 30 kD.  From the protein sequence, GST alone is approximately 26 kD while 
the GST-GnRH3 fusion protein is 29kD.   
Western blot analysis was used to verify the specificity of the recombinant GST-
GnRH3 protein (Figure 6).  The anti-GnRH serum bound to bands in the area of 30 kD.     
Follicular Development and Estrous Behavior 
The GST-GnRH3 vaccine suppressed follicular activity in all treated mares 
following the second immunization (Figure 7).  One of the anti-GnRH mares (T-2) 
displayed only small follicles (<10 mm) within the first two days following the second 
injection while the other three anti-GnRH mares (T-1, T-3, T-4) displayed only small 
follicles within 45 days after the second injection.  Follicles and ovaries of all anti-GnRH 
mares remained small and inactive through the end of the study. 
At time of the second injection two anti-GnRH (T-2, T-4) mares had large (> 40 
mm) follicles present on their ovaries (Figure 7).   One mare (T-2) ovulated this follicle 2 
days after the injection and no estrous behavior or ovarian activity was observed from 
this point throughout the end of the study.  The large follicle on the ovary of the other 
anti-GnRH mare (T-4) slowly regressed over 5 weeks.  This mare began to display 
continuous estrous behavior 2 weeks following the second immunization which lasted for 
7 consecutive weeks despite the lack of ovarian activity during the latter half of this 
period.  The other two anti-GnRH treated mares (T-1, T-3) both had 28 mm and 23 mm 
follicles, respectively, at the time of the second injection.   
Estrous behavior was suppressed in 3 of the 4 anti-GnRH mares following the 
second injection (Figure 8).  One anti-GnRH treated mare (T-4) displayed strong estrous 
behavior for seven weeks following the second injection before behavior ceased.  One of 
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the control mares (C-1) exhibited normal 21 day estrous cycles with normal estrous 
behavior throughout the study.  The other control mare (C-2) cycled normally until the 
beginning of August in which large follicles developed but failed to ovulate.  This control 
mare did not display estrous behavior and progesterone levels remained moderately high 
(4.6ng/ml) for 6 weeks towards the end of the study.  
 
Serum Progesterone 
Progesterone concentrations fluctuated between 0.29 ng/ml and 13 ng/ml 
depending on the stage of the estrous cycle during the first 5 weeks prior to primary 
immunization (Figure 9).  Before the second injection mean progesterone concentrations 
of the anti-GnRH (4.06±0.46 ng/ml) and control mares (4.00 ± 0.65 ng/ml) were similar; 
whereas, the mean progesterone concentration were significantly lower (p<0.01) for the 
anti-GnRH mares (0.95 ± 0.38 ng/ml) as compared to the control mares (4.07 ± 0.54 
ng/ml) following the second injection (Table 1).  Mean progesterone concentrations of 
the control mares varied due to the stages of their estrous cycle, although levels remained 
above 2.5 ng/ml during the period in which one of the control mares (C-2) failed to 
ovulate (Figure 9).  Three weeks after the second injection all anti-GnRH treated mares 
demonstrated anestrous-like progesterone profiles (<1.0 ng/ml), which remained low 
throughout the final 9 weeks of the study. 
Serum Binding of GnRH 
Binding of GnRH with serum from both anti-GnRH (0.27 ± 0.12 A450 nm) and 
control (0.20 ± 0.12 A450 nm) mares was similar up to the second immunization.  
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However, following the second immunization binding of GnRH with serum from anti-
GnRH mares (0.59 ± 0.11 A450nm) was significantly higher (p<0.01) than binding of the 
control mares (0.33 ± 0.12 A450 nm; Table 1).  GnRH binding for anti-GnRH mares 
peaked at week 6; two weeks following the second injection (Figure 10).   
Adverse Reactions 
Adverse injection reactions were observed in all but one anti-GnRH mare as well 
as both control mares.  Adverse reactions were defined as visible granulomas (Figure 11) 
and elevated temperatures ranging from 39°C to 40°C.  Horses with fevers were treated 
twice daily with 0.5 mg/kg body weight of Banamine® (flunixin meglumine) until 
temperatures subsided.  All fevers occurred within 7 days of immunization and subsided 
in 2-5 days.  Granulomas appeared 24 hours post primary injection and all were reduced 
to only a small palpable knot within one week.  No granulomas were found in the hind 
quarters after the second injection.  Three months following the primary injection one of 
the anti-GnRH mares developed a granuloma in the region of the first injection (right 
neck) which was still visible at the end of the study.  
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Discussion   
The pGEX-4T vector is commercially designed to produce fusion proteins 
through the use of GST-glutathione binding affinity.  GST and GST fusion proteins can 
be recovered with elution by free reduced glutathione (Smith and Corcoran, 1994).  
Previously in our laboratory, one factor impeding the yield of GST-GnRH3 fusion 
protein was formation of insoluble proteins (inclusion bodies) after plasmid expression in 
E. coli (Holladay et al., 2003).     
N-laurolysarcosine buffer was tested in the present study to reduce insoluble GST 
fusion proteins (Sambrook and Russell, 2001).  Although, Hull et. al. (1992) saw 
improved recovery of soluble protein after using this buffer, this was not the case in the 
present study.  It was found that the 3-hour incubation without sarcosine buffer 
preparation produced the highest fusion protein yields.  It is possible that combining the 
soluble pellet resuspension with the sarcosine buffer treatment suspension reduced yield, 
increased precipitate, and subsequently decreased binding to the affinity column.    
The recombinant GnRH vaccine suppressed cyclicity and serum progesterone in 
each of the anti-GnRH mares following the second injection through the remainder of the 
study.  All anti-GnRH mares reached this state within 45 days following the second 
immunization.  The ultrasound data confirmed that ovaries were in an anestrous state due 
no evidence of a CL present and only small diameter follicles visible on the ovarian 
surface.  Increased serum binding of GnRH following the second immunization 
demonstrated the presence of endogenous anti-GnRH antibodies.  Presumably this 
binding prevented GnRH from binding to gonadotroph receptors in the anterior pituitary, 
thereby decreasing the release of LH and FSH.  
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The recombinant GnRH vaccine used in this study suppressed follicular activity 
and cyclicity in mares similar to a previous report for heifers (Holladay et al., 2003). This 
immunocontraception strategy was also effective in mares treated with conjugated GnRH 
vaccines (Dalin et al., 2002; Elhay et al., 2007; Imboden et al., 2006; Tshewang et al., 
1997).  GnRH vaccines have also been successful at reducing serum testosterone levels 
and sperm motility in sexually mature stallions (Turkstra et al., 2005) and colts (Dowsett 
et al., 1993).  Moreover, this method of immunocontraception was proven to be 
reversible in studies which evaluated return to estrus or functional reproduction (Dalin et 
al., 2002; Dowsett et al., 1993; Elhay et al., 2007; Holladay et al., 2003; Imboden et al., 
2006; Tshewang et al., 1997).  In our study two of the anti-GnRH mares were available to 
be examined one year after the initiation of treatment.  One of the mares had a CL while 
the other had a large follicle but no evidence of a CL at the time of ultrasonography.  
These results suggest a return to cyclicity is possible in the subsequent breeding season 
following vaccine treatment.  
Continuous estrous behavior in the absence of ovarian activity was observed in a 
previous study using an anti-GnRH vaccine (Dalin et al., 2002) as well as in 
ovariectomized or anovulatory mares (Ginther, 1992). This behavior is hypothesized to 
be initiated by the release of estrogenic steroids from the adrenals (Crowell-Davis, 2007).  
However, in our current study one anti-GnRH mare (T-4) was developing a large follicle 
at the time of the second injection.  Rather than ovulate, this large follicle regressed 
slowly until undetectable through ultrasonography and no significant structures were 
visible on the ovary throughout the rest of the study.  Since this was the treated mare that 
displayed continuous estrous type behavior it is possible that this slowly regressing 
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follicle was a factor.  The treated mare which received the second immunization just prior 
to ovulation established an anestrous like ovary and suppressed estrous behavior almost 
immediately following injection.  Due to this finding, it may be best to immunize just 
prior to or following ovulation so that slowly regressing follicles do not present a source 
of estrogen.    
It was unclear why one of the control mares built follicles which failed to ovulate 
during the latter part of the study, although after evaluating progesterone data it is 
possible that persistent luteal tissue was undetected with ultrasonography.  This mare 
proved to be difficult to ultrasound throughout the study and the presence of luteal tissue 
was questioned during scanning.  In a comparable study, Dalin and coworkers (2002) 
reported one mare that failed to ovulate three months after immunization and then 
displayed some cyclic activity 5 and 7 days prior to entering seasonal anestrous.  We 
hypothesize that due to elevated progesterone levels and the absence of ovulation and 
estrous behavior the control mare in the present study sustained a persistent CL.  
The adverse reactions to the immunizations reported here were similar to those 
observed in earlier reports (Dalin et al., 2002; Elhay et al., 2007; Imboden et al., 2006).  
Each of these studies investigated different GnRH conjugates and adjuvants and though 
the severity of reactions varied, they cause concern about the safety of GnRH vaccines.  
Adverse reactions in the mares in the present study were thought to be caused by the 
adjuvant or carrier protein as they occurred in both the anti-GnRH and control mares.  
Results from this study demonstrated a significant reduction in adverse reactions when 
both the adjuvant and antigen dose was reduced in half and then administered in the mid-
gluteal region.  This region may be the best site for injection due to the continuous 
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flexing and movement of this muscle reducing the possibility for the formation of a 
granuloma.  It is also important to evaluate different adjuvants used as 
immunostimulators for this type of contraception.  Researchers are currently investigating 
the use of CpG motif-based adjuvants in recombinant GnRH vaccines (Conforti et al., 
2007) and synthetic GnRH vaccines which includes three linear repeats of GnRH, the 
hinge region of human IgG1 (hinge), and a T-helper epitope from the measles virus 
protein (MVP), conjugated to a purified recombinant heat shock protein 65 (Hsp65) of 
Mycobacterium bovis, as an alternative for common adjuvants (Jinshu et al., 2005).   
In conclusion, the GST-GnRH3 vaccine was effective in suppressing follicular 
development and progesterone concentrations in mares by stimulating antibody 
production against GnRH.  In this study with a limited number of animals, estrous 
behavior was suppressed in all but one treated mares.  This type of vaccine is beneficial 
for suppressing estrous behavior in mares that are often exposed to a stallion during 
competition or working situations.  Immunocontraception also provides the owner with 
the option of breeding the mare later in life.  However, for this method to be safe, 
effective and practical, an optimal dose of antigen and adjuvant needs to be determined. 
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Figure 1.  A map of the pGEX-GnRH3 protein expression plasmid. 
(A) A 90bp coding sequence coding for 3 copies of GnRH was inserted at the BamH I     
 restriction site of pGEX-4T-3.  (B) The sequence of the coding region downstream of 
GST:  The 3 tandem repeated coding region of GnRH is highlighted in green and the 
recognition site for BamH I in purple.  
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Figure 2.  Experimental design. 
(A) Immunization schedule.  (B) Weekly data collections of ultrasound (U/S), teasing and 
bleeding. 
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Figure 3.  Restriction endonuclease digest of the pGEX-GnRH3 plasmid. 
An ethidium bromide stained agarose gel loaded with 100bp DNA ladder (lane 1), the 
undigested pGEX-GnRH3 plasmid (lane 2), BamH I (lanes 3 and 4), BamH I and EcoRV 
(lanes 5 and 6) and a 1.0kb DNA ladder (lane 7).  The bold arrow indicates the 90bp 
GnRH-3 BamH I fragment.     
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Figure 4.  Restriction endonuclease digest of the pGEX-4T vector. 
An ethidium bromide stained agarose gel was loaded with 100bp DNA ladder (lane 1), 
undigested pGEX-4T (lane 2), BamH I digest (lanes 3 and 4) and 1.0kb DNA ladder 
(lane 5). 
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Figure 5.  Coomassie blue stained gel of GST-GnRH3 fusion protein. 
An acrylamide gel loaded with GST-GnRH3 protein from the 3-hour incubation without 
sarcosine treatment (lanes 1: 3mg, and lane 2: 6mg), overnight incubation with sarcosine 
treatment (lane 3), overnight incubation without sarcosine treatment (lane 4), 20 ug of 
BSA (lane 5), and molecular weight standards (lane 6). 
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Figure 6.  Western blot analysis of GST-GnRH3 fusion protein. 
A PVDF membrane was probed with rabbit anti-GnRH.   Lanes 1 and 2 were loaded with 
GST-GnRH3; lane 3 contained purified GnRH for control;  and lane 4 was loaded with 
molecular weight standards.  Bold arrows depict the purified GnRH band (lane 3) and the 
GST-GnRH3 band (lane 1). 
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Figure 7.  Ovarian ultrasonography data for individual mares. 
T-1, T-2, T-3 and T-4 represent the four anti-GnRH treated mares, while C-1 and C-2 
represent the two control mares.  The arrows indicate times of the immunizations.  Small 
follicles were categorized to be approximately ≤10mm, medium follicles 11-15mm and 
large 16-20mm.  A post ovulation CL was arbitrarily assigned a 5mm designation.
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Figure 8.  Teasing scores for individual mare after exposure to a stallion. 
Estrous behavior of anti-GnRH (T-1, T-2, T-3 and T-4) and control (C-1 and C-2) mares.  
Teasing behavior was evaluated when exposed to a stallion and mares were assigned a 
score of 1-5.  Arrows indicate times of the immunizations.  
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Figure 9.  Serum progesterone profiles for individual mares. 
The progesterone profiles of each anti-GnRH mare (T-1, T-2, T-3 and T-4) and control 
mares (C-1 and C-2).  Arrows indicate times of the two immunizations. 
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Figure 10.  Serum binding of the GnRH. 
The circles indicate the GnRH binding of serum from anti-GnRH mares (n=4) while the 
squares indicated GnRH binding of serum from control mares (n=2).  Arrows indicate 
times of the immunizations. 
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Figure 11.  Injection site granuloma from an anti-GnRH mare.  
Photograph was taken two days after the primary immunization.  The circled area 
represents the area of a granuloma. 
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Table 1.  Mean serum progesterone concentration and GnRH binding. 
Mean progesterone concentration and GnRH binding in Anti-GnRH immunized mares 
and Control mares before 2nd immunization (-5 to 3 wk) and after 2nd immunization (4 
to 16 wk). 
 
 
*Significant differences (p<0.01) within columns with different superscripts. 
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